PTGS2 and invasive breast carcinoma: Our study on 212 patients with invasive breast cancer confirms previous reports that COX-2 overexpression is rather frequent in this patient population (Soslow et al, 2000) and predicts a dismal prognosis for breast cancer patients (Ristimaki et al, 2002).